Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.3Single regulatory cell per chamber
What ifWhat if each assay chamber received one receptor-bearing thymus-derived regulatory T cell?
Claim language“a Thy Treg cell population”
A single-cell dispenser places one regulatory T cell in each chamber with antigen-presenting cells and labeled responder T cells. Time-lapse imaging records responder-cell divisions and compares division counts with control chambers.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Regulatory cells for veterinary graft studies
A veterinary kidney transplant research system uses canine thymus-derived regulatory T cells that express a chimeric antigen receptor with extracellular recognition, hinge, transmembrane, costimulation, and stimulation domains. The recognition domain binds a cell-surface antigen present on donor kidney tissue. A co-culture places the regulatory cells, donor kidney tissue, and recipient responder T cells in the same chamber and measures responder proliferation as the readout of local suppression.
Component substitution
Short CD8 alpha receptor hinge
A CD8 alpha stalk segment replaces the receptor hinge between the extracellular antigen-binding domain and the transmembrane domain. The stalk connects the binding domain to the cell membrane and sets how far the binding domain projects from the surface. The transmembrane domain anchors the receptor, and the intracellular costimulation and stimulation domains transmit signals within the thymus-derived regulatory T cell.
Parameter or scale variation
Three ratios for suppression measurements
A co-culture assay holds the responder T-cell count and the number of antigen-bearing stimulator cells constant while varying the number of receptor-expressing thymus-derived regulatory T cells. The plate includes triplicate wells at regulatory-to-responder ratios of 1:1, 1:2, and 1:4 and triplicate responder controls at 0:1. A proliferation dye labels the responder cells before plating, and flow cytometry measures the fraction of responders that divide after 72 hours.
Combination with existing systems
Flow chamber with an endothelial lining
A recirculating microfluidic flow chamber contains a layer of endothelial cells that display the antigen recognized by the receptor. A pump circulates medium containing fluorescently labeled receptor-expressing thymus-derived regulatory T cells through the endothelial channel. Time-lapse microscopy records cell contact duration and surface retention, with a parallel channel lined by antigen-negative endothelial cells serving as a control.
Separate culture chambers for suppression assays
A two-chamber culture insert uses a 0.4-micrometer porous membrane to separate receptor-expressing thymus-derived regulatory T cells and antigen-bearing stimulator cells in the upper chamber from activated responder T cells in the lower chamber. Soluble factors diffuse between the chambers while the membrane retains the cells in their original compartments. Parallel wells containing all three cell populations in one chamber provide a comparison for responder proliferation when direct contact is possible.
Automated or data-driven variant
Automated cytometry for receptor expression
A flow cytometer collects scatter, viability, and receptor-label fluorescence measurements from each sample of thymus-derived regulatory T cells. Software excludes debris, doublets, and dead cells, then applies a receptor-label threshold set from a matched population of unmodified cells. The software reports the receptor-positive fraction, median receptor-label fluorescence, and event count for each sample.
Specific version of a part
Co-stimulation through a separate receptor
The engineered receptor delivers the primary signal when it binds surface antigen on a presenting cell. A co-stimulatory ligand on that cell engages native CD28 on the regulatory T cell and supplies the second signal.
Primary stimulation through peptide presentation
A presenting cell displays a peptide recognized by the regulatory T cell and a separate surface antigen recognized by the engineered receptor. The native T-cell receptor supplies primary stimulation, while the engineered receptor contributes co-stimulation.
Full reference co-stimulation sequence
The full amino acid sequence identified as SEQ ID NO: 1 forms the intracellular co-stimulation segment and has 100% identity to the reference. An antigen-dependent coculture assay measures suppression of responder T-cell proliferation as a regulatory response.
Three-motif primary activation tail
The CD3 zeta cytoplasmic tail supplies three tyrosine-based activation motifs. Receptor engagement promotes phosphorylation of the motifs and recruitment of an intracellular kinase that propagates the activation signal.
Enriched thymus-derived regulatory cell population
Cell sorting enriches thymus-derived CD4 T cells with high CD25 and low CD127 surface expression. A receptor-specific fluorescent probe identifies surface receptor expression within the enriched population.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a cytoplasmatic co-stimulation domain with a sequence having an identity of at least 85% with respect to SEQ ID NO: 1 which provides a signal mediating a Treg cell specific response; and
The signalling domain is usually comprised of elements of the CD3 zeta (CD3ζ) chain activation domain which provides TCR-like stimulation (termed signal 1) and elements of the CD28, CD137 (4-1BB), CD134 (OX40), CD244 or ICOS signalling moieties that provide co-stimulatory signals (termed signal 2).
A · US 2018/0125889 A1 · ¶ 18
In one embodiment, the cytoplasmic domain in the CAR of the invention is designed to comprise the signaling domain of 4-1BB and the signaling domain of CD3-zeta, wherein the signaling domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 30 or a functional variant thereof and the signaling domain of CD3-zeta comprises the amino acid sequence of SEQ ID NO: 31 or a functional variant thereof.
B · US 2022/0184119 A1 · ¶ 245
1.2a cytoplasmatic stimulation domain;
The signalling domain is usually comprised of elements of the CD3 zeta (CD3ζ) chain activation domain which provides TCR-like stimulation (termed signal 1) and elements of the CD28, CD137 (4-1BB), CD134 (OX40), CD244 or ICOS signalling moieties that provide co-stimulatory signals (termed signal 2).
A · US 2018/0125889 A1 · ¶ 18
The CAR of the invention comprises a primary cytoplasmic signaling sequence derived from CD3-zeta.
B · US 2022/0184119 A1 · ¶ 241
1.3or a Thy Treg cell population comprising or consisting thereof.
An empty cell means only that no passage was reproduced there.
Statements in these documents
Thus, alternative and/or improved treatment strategies using gamma delta T cells are required.
A · US 2018/0125889 A1 · ¶ 4
This application relates to methods of preparing and using gamma delta T cells (γδ T cells), suitably the use of gamma delta T cells in allogeneic or autologous recipient subjects for the treatment of conditions including virus infection, fungal infection, protozoal infection and cancer, specifically to the use of chimeric antigen receptors (CARs) modified γδ T cells.
A · US 2018/0125889 A1 · ¶ 1
Thus, there is an urgent need in the art for effective compositions and methods for treatment of cancer using CARs.
B · US 2022/0184119 A1 · ¶ 3
We could demonstrate highly specific and sensitive recognition of CLDN6 expressing target cells as well as a high potential for survival and repetitive stimulation of CAR T cells.
B · US 2022/0184119 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355243 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355243/, SHA-256 ef496313cf5d735927597d639b89a206b11ab7e895b1f0fa2cd88827f3d9b3de